MENU

NKX019 Safety Data: Nkarta’s CAR NK Therapy for Autoimmune Diseases

Yahoo Finance USA
Overview
Nkarta reported no cases of CRS, ICANS, IEC-HS, or GvHD across 40 patients treated with NKX019 for five autoimmune diseases. The data indicates a favorable safety profile with no deaths or treatment discontinuations due to adverse events. This suggests CAR NK cells may provide a safer alternative to CAR T cells by limiting in vivo expansion.
In Depth

Key Safety Findings

Integrated safety analysis of 40 patients in the Ntrust program showed no reported cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), or graft-versus-host disease (GvHD). There were no deaths and no treatment discontinuations resulting from adverse events. Additionally, no cases of fludarabine-associated leukoencephalopathy were reported.

Technical Details and Patient Cohort

The analysis included patients with systemic sclerosis, myositis, lupus nephritis, rheumatoid arthritis, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The cohort consisted of patients with active or progressive disease; 75% (30 patients) had received four or more prior treatments, with a median disease duration of 4.7 years. Patients underwent outpatient lymphodepleting preconditioning using fludarabine and cyclophosphamide before receiving a three-dose cycle of NKX019.

  • Dosing Distribution: 70% (28 patients) received 4 billion cells, 17.5% (7 patients) received 2 billion cells, and 12.5% (5 patients) received 1 billion cells.
  • Adverse Events: Treatment-emergent adverse events occurred in 85% (34 patients). Grade 3 or higher events occurred in 35% (14 patients), primarily hematologic issues attributed to lymphodepletion.
  • Infusion Reactions: 12.5% (5 patients) experienced infusion-related reactions associated with NKX019 (four grade 1, one grade 3), all of which resolved within 24-48 hours without the use of tocilizumab.

Background and Biological Context

NKX019 is an allogeneic, off-the-shelf, CD19-directed CAR NK cell therapy. According to Nkarta CEO Paul J. Hastings, CAR NK cells differ from CAR T cells because they are designed for targeted B-cell depletion with limited in vivo expansion and more predictable cellular exposure. This biological difference is intended to avoid the toxicities typically associated with autologous T cell-based modalities.

Significance and Outlook

The data, presented at ACR Convergence 2026 with a cutoff date of September 18, 2026, suggests that the safety profile of NKX019 remains consistent regardless of dose, as no increase in adverse events was observed at higher doses.

Source: https://finance.yahoo.com/healthcare/articles/nkarta-presents-initial-safety-data-120000700.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

  • Your email and selected fields are used only to deliver the newsletter.
  • We never share your information with third parties.
  • You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Takes about a minute · Unsubscribe anytime

Published by Troy-Technical, an independent site run by one engineer with a career in materials development.
About the author / Contact info@troy-technical.jp
Let's share this post !

Author of this article

TOC